LMB:NASDAQLimbach Holdings, Inc. Analysis
Data as of 2026-06-22 - not real-time
$80.15
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Limbach Holdings (LMB) is trading at $80.15, just above its 20‑day SMA of $79.14 but still below the 50‑day ($83.75) and 200‑day ($85.16) averages, indicating a short‑term bounce within a longer‑term bearish backdrop. The RSI sits at 49.8, suggesting neutral momentum, while the MACD histogram is positive and the MACD line sits above its signal, hinting at a modest upside catalyst. Volatility is elevated at nearly 60% over the past 30 days and the stock’s beta exceeds 1.3, underscoring heightened sensitivity to market swings. On the fundamentals side, revenue grew modestly 4.3% YoY to $652 M, but margins remain thin (gross 25%, operating Analyst consensus is bullish (Buy) with a mean target of $116.6, driven by a low forward PE of 15.9 and strong ROE (~19%).
Despite the bullish analyst outlook, the combination of high leverage, shrinking volume, and pronounced price volatility suggests caution. The stock sits between a support level of $70.5 and resistance near $85.8, leaving limited upside unless it can break the resistance and sustain higher volumes. Investors should weigh the upside potential against the valuation disconnect and sector cyclicality before committing.
Despite the bullish analyst outlook, the combination of high leverage, shrinking volume, and pronounced price volatility suggests caution. The stock sits between a support level of $70.5 and resistance near $85.8, leaving limited upside unless it can break the resistance and sustain higher volumes. Investors should weigh the upside potential against the valuation disconnect and sector cyclicality before committing.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price hovering between support and resistance
- bearish longer‑term trend despite short‑term MACD bullishness
- decreasing trading volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- low forward PE relative to peers
- positive free cash flow and solid ROE
- analyst consensus and target price upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- significant valuation gap between market price and DCF fair value
- high debt burden and sector cyclicality
- sustained earnings growth potential
Key Metrics & Analysis
Financial Health
Revenue Growth4.30%
Profit Margin5.09%
P/E Ratio29.3
ROE18.59%
ROA7.78%
Debt/Equity38.95
P/B Ratio4.9
Op. Cash Flow$35.6M
Free Cash Flow$18.6M
Industry P/E31.4
Technical Analysis
TrendBearish
RSI49.8
Support$70.51
Resistance$85.79
MA 20$79.14
MA 50$83.75
MA 200$85.16
MACDBullish
VolumeDecreasing
Fear & Greed Index91.23
Valuation
Fair Value$19.65
Target Price$116.60
Upside/Downside45.48%
GradeOvervalued
TypeBlend
Risk Assessment
Beta1.32
Volatility59.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.